七月 2026
- Home
- Vera Therapeutics
七月 2026的Vera Therapeutics市场份额分析
Vera Therapeutics Executive Leadership Team and Board of Directors provide strategic guidance informed by deep expertise in scientific, clinical, operational, and financial experience.
Vera Therapeutics(包含公司地区分支机构)
查看更多网站流量和参与度信息- veratx.com
Vera Therapeutics热门域名的总访问量
了解Vera Therapeutics市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Vera Therapeutics热门域名的平均访问时长
分析Vera Therapeutics参与度指标。
过去 3 个月的平均访问时长
子公司明细
Vera Therapeutics热门域名的平均页面浏览量
了解Vera Therapeutics如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Vera Therapeutics 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Vera Therapeutics, Inc. identified as competitor of Otsuka Us on Jul 1st '26.Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with Otsuka's recently approved anti-APRIL drug Voyxact.
七月 8, 2026阅读更多
新闻Vera Therapeutics, Inc. identified as competitor of Novartis AG on Jul 7th '26.Vera Therapeutics' atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA approval.
七月 7, 2026阅读更多
新闻Vera Therapeutics, Inc. identified as competitor of Vertex Pharmaceuticals on Jul 7th '26.Vera Therapeutics Inc. looks to get an almost five-month head start over a competitor, Vertex Pharmaceuticals Inc., as the U.S. FDA cleared its Trutakna (atacicept) as the first dual BAFF/APRIL inhibitor for treating immunoglobulin A nephropathy (IgAN).
七月 7, 2026阅读更多
查看 Vera Therapeutics 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
